The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Xeris Biopharma Holdings Inc shares valued at $10,314 were purchased by Schmid John P. on May 10 ’24. At $1.91 per share, Schmid John P. acquired 5,400 shares. The insider’s holdings grew to 16,400 shares worth approximately $39852.0 following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Schmid John P. purchased 4,500 shares, netting a total of over 9,720 in proceeds. Following the buying of shares at $2.16 each, the insider now holds 11,000 shares.
Before that, SHERMAN JEFFREY W had added 5,400 shares to its account. In a trade valued at $10,098, the Director bought Xeris Biopharma Holdings Inc shares for $1.87 each. Upon closing the transaction, the insider’s holdings increased to 5,400 shares, worth approximately $13122.0.
As published in their initiating research note from Oppenheimer on March 28, 2024, Xeris Biopharma Holdings Inc [XERS] has been an Outperform and the price target has been revised to $5. Analysts at Craig Hallum started covering the stock with ‘”a Buy”‘ outlook in a report released in late August. As of October 21, 2022, Jefferies has initiated its “Buy” rating for XERS. Earlier on April 28, 2022, Craig Hallum initiated its rating. Their recommendation was “a Buy” for XERS stock.
Analyzing XERS Stock Performance
During the last five days, there has been a surge of approximately 25.91%. Over the course of the year, Xeris Biopharma Holdings Inc shares have jumped approximately 3.40%. Shares of the company reached a 52-week high of $3.26 on 02/15/24 and a 52-week low of $1.69 on 04/26/24. A 50-day SMA is recorded $1.96, while a 200-day SMA reached $2.13. Nevertheless, trading volume fell to 1.74 million shares from 1.85 million shares the previous day.
Support And Resistance Levels for Xeris Biopharma Holdings Inc (XERS)
According to the 24-hour chart, there is a support level at 2.35, which, if violated, would cause prices to drop to 2.28. In the upper region, resistance lies at 2.47. The next price resistance is at 2.52. RSI (Relative Strength Index) is 69.26 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.30, which suggests the price will decrease in the coming days. Percent R is at 12.31%, indicating bullish price movement. Stochastics %K at selling indicates that the stock is to be held.
